遺伝子治療薬の世界市場:免疫疾患

◆英語タイトル:Gene Therapy Immunology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape
◆商品コード:DELVGT502009
◆発行会社(調査会社):DelveInsight
◆発行日:2015年1月
◆ページ数:75
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Summary
DelveInsight’s Report: Gene Therapy Immunology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The Gene Therapy Immunology Report provides the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. Using the propriety DelveInsight Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies and pre-clinical therapies in a demographic presentation view.

Report facts
DelveInsight Gene Therapy Immunology Report: “Gene Therapy Immunology Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape” provides in depth insights into the Immunology gene therapy. It has covered 10+ gene therapies covering 5+ Pharmaceutical companies. Studies are performed for approximately 10+ specific indications under Immunology. The Companies are utilizing 5 different technology platforms which have its own uniqueness and robustness. The Report is also giving insights about the vectors usage in Gene therapy which is approximately 55% for viral vectors, 27% for RNAi therapeutics and 18% for Non Viral vectors. The Report is also giving early winners of the Immunology gene therapy market using DelveInsight proprietary Matrix Model.

Reports Highlights:
• Global Gene Therapy Overview & Pipeline Insights
• Trends in gene therapy partnering deals
• Current Prominent Research Areas and Key Players
• Companies Targeting Prominent Therapeutic Areas
• Number of Gene Therapies in Clinical Trials
• Number of Gene Therapies by Vectors used
• Technology and their innovative Companies
• Early Market Winners for Gene Therapy

Scope
• A snapshot of the global Gene therapy market scenario, market trends & drivers, manacles of gene therapy.
• A review of the marketed Gene therapy products and marketing status
• Coverage of global gene therapies under development across the globe covering territories
• Competitive landscape of investigational products for key players and key therapy areas.
• The Gene Therapy report covers the product description, stage of development, licensors & collaborators, Development partner and Technology information
• The Report also provides the pre-clinical and clinical outcomes of the gene therapies
• The Report has covered the vector used, target genes, localization of gene and detailed mechanism of action
• Report has highlighted the licensing opportunities and funding details for gene therapies
• The report also gives the information of dormant and discontinued pipeline projects
• Market Analytics of Gene Therapies using DelveInsight Propriety Model.

Reason to Buy
• Complete Market and Pipeline intelligence and complete understanding over therapeutics development for gene therapy
• Devise corrective measures for pipeline projects by understanding Therapy area specific gene therapies
• Developing strategic initiatives to support your gene therapy development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Evaluate the marketing and pipeline strategy for gene therapies and their Funding availabilities.
• Identifying the upcoming leaders in the gene therapy market in the coming years.
• Getting a first mover advantage by identifying the early market winners for clinical and preclinical gene therapies.

【レポートの目次】

[Table of Contents]

Introduction
Global Gene Therapy Market & Pipeline Insight Market Highlight
Gene Therapy- An Upcoming Innovation of Genetic Medicines
Internationally Recognized Gene Symbols
Driving Factors for Growing Popularity of Gene Therapy
Market Manacles for Gene Therapy
Current Research Therapeutic Areas in Gene Therapy Market
Ex vivo and In vivo Approaches of Gene Therapy
Types of Vectors developed for Gene Therapy
Marketed and Pipeline Drugs for Gene Therapy
Marketed Products Scenario for Gene Therapies
Rexin G Profile
Technology Description
Funding Agreement
Gendicine Profile
Technology Description
Funding Agreement
Glybera Profile
Technology Description
Funding Agreement
Assessment of Marketed Drugs by Therapeutic Approach
Assessment of Marketed Drugs by Route of Administration
Assessment of Marketed Drugs by Delivery System
Pipeline Gene Therapy Products under Immunology
Gene Therapy Products Distribution on the Basis of Delivery System Developed
Gene Therapy Products Distribution on the Basis of Genetic Material Transfer Techniques
Gene Therapies Profiles
Product Description
Product Technology Description
Product Funding Agreement
Product Pre-clinical Outcomes
Product Clinical Outcomes
Discontinued Products
Dormant Products
DelveInsight Competitive Matrix
Early Winners for Gene therapy
Report Methodology
Secondary Research
Primary Research
Expert Panel Validation
About DelveInsight
Contact Us

[LIST OF TABLES]

Table 1: Human Genome Statistics, 2015
Table 2: Statistics for Various Locus Type under Non-Coding RNA, 2015
Table 3: Statistics for Various Locus Type under Pseudogenes, 2015
Table 4: Statistics for Various Locus Type under Non-Coding RNA, 2015
Table 5: Most Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Table 6: Less Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Table 7: Number of Companies Targeting Therapeutic Areas for Gene Therapy, 2015
Table 8: Number of Gene Therapy Products of Prominent Therapeutic Areas in Clinical Trials, 2015
Table 9: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%), 2015
Table 10: Distribution of Companies Based on the Genetic Material Transfer Techniques (%), 2015
Table 11: Number of Gene Therapy Products Addressed to Different Types of Vectors, 2015
Table 12: Marketed and Pipeline Gene Therapy Products, 2015
Table 13: Therapeutic Areas of Marketed Gene Therapy, 2015
Table 14: Number of Gene Therapy Products under Development for Immunology, 2015
Table 15: Number of Gene Therapy Products Addressed to Different Types of Vectors Immunology, 2015
Table 16: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%) for Immunology, 2015
Table 16: Companies and Number of Gene Therapies for Immunology, 2015
Table 17: Companies and Number of Gene Therapies in Clinical Trials for Immunology, 2015
Table 18: Indications and Number of Gene Therapies in Clinical Trials for Immunology, 2015
Table 19: Discontinued Products, 2015
Table 20: Dormant Products, 2015

[LIST OF FIGURES]

Figure 1: Human Genome Statistics, 2015
Figure 2: Statistics for Various Locus Type under Non-Coding RNA, 2015
Figure 3: Statistics for Various Locus Type under Pseudogenes, 2015
Figure 4: Statistics for Various Locus Type under Non-Coding RNA, 2015
Figure 5: Most Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Figure 6: Less Prominent Therapeutic Areas under Research for Gene Therapy, 2015
Figure 7: Number of Companies Targeting Therapeutic Areas for Gene Therapy, 2015
Figure 8: Number of Gene Therapy Products of Prominent Therapeutic Areas in Clinical Trials, 2015
Figure 9: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%), 2015
Figure 10: Distribution of Companies Based on the Genetic Material Transfer Techniques (%), 2015
Figure 11: Number of Gene Therapy Products Addressed to Different Types of Vectors, 2015
Figure 12: Marketed and Pipeline Gene Therapy Products, 2015
Figure 13: Therapeutic Areas of Marketed Gene Therapy, 2015
Figure 14: Number of Gene Therapy Products under Development for Immunology, 2015
Figure 15: Number of Gene Therapy Products Addressed to Different Types of Vectors for Immunology, 2015
Figure 16: Distribution of Gene Therapy Products Based on the Genetic Material Transfer Techniques (%) for Immunology, 2015
Figure 16: Companies and Number of Gene Therapies for Immunology, 2015
Figure 17: Companies and Number of Gene Therapies in Clinical Trials for Immunology, 2015
Figure 18: Indications and Number of Gene Therapies in Clinical Trials for Immunology, 2015



【レポートのキーワード】

免疫疾患、遺伝子治療、製薬、パイプライン

★調査レポート[遺伝子治療薬の世界市場:免疫疾患] (コード:DELVGT502009)販売に関する免責事項を必ずご確認ください。
★調査レポート[遺伝子治療薬の世界市場:免疫疾患]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆